Transcript Opportunities to bridge the technology gap between

Proprietary and Confidential © AstraZeneca 2008
FOR INTERNAL USE ONLY
Opportunities to bridge the technology gap
between academia and industry.
The view from one pharma
AstraZeneca
• Major world wide Pharma
• Active in more than 100 countries world wide
• 2008 sales of $31.6 billion
• >3% increase on 2007
• 65,000 employees world wide
• 12,000 staff in R&D
• >$5 billion invested in R&D
• 17 principle R&D centers across 8 countries
• Focus on 6 therapy areas
• Oncology
• Cardio Vascular
• Respiratory and Inflamation
• Infection
• Neuroscience
• Gastrointestinal
Proprietary and Confidential © AstraZeneca 2008
FOR INTERNAL USE ONLY
Pipeline of NCEs as of Jan 2009
• Phase 1 trial
• 23 small molecules
• 10 biologicals
• Phase 2 trials
• 26 small molecules
• 5 biologicals
• Phase 3/ registrations
• 9 small molecules
• 1 biological
•
Data from 2008 annual report
Proprietary and Confidential © AstraZeneca 2008
FOR INTERNAL USE ONLY
Acquisitions and Licensing
Proprietary and Confidential © AstraZeneca 2008
FOR INTERNAL USE ONLY
• 35-40 major business development transactions (2008 annual report)
• Some examples of recent acquisitions
• Biologicals
• Cambridge Antibody Technologies
• MedImmune
• Infection
• Arrow Therapeutics
• Oncology
• KuDos Pharmaceuticals
• Licensing
• 11 of the NCEs currently in clinical trials are partnered products
Links with Academic Institutions
Proprietary and Confidential © AstraZeneca 2008
FOR INTERNAL USE ONLY
• Within the UK
• 2008 started collaboration with Cancer Research UK – Linking an
AstraZeneca development compound with the charities Clinical
Development Partnership program
• Royal Marsden NHS foundation trust – accessing imaging technology to
study the impact of Recentin on solid tumours
• Manchester University – strategic alliance to look at imaging
biomarkers. In addition there are links through Manchester University to
the National Cancer Centre Singapore
• Newcastle University – linked with Astrazeneca via Cancer Research
Technology Ltd and KuDOS to study DNA-PK inhibitors
• MRC – 4 PhDs
• BBSRC – AstraZeneca linked with the Babraham Institute
• Division of Signal Transduction Therapy – University of Dundee
Links with Overseas Academics
Proprietary and Confidential © AstraZeneca 2008
FOR INTERNAL USE ONLY
• ICC – Innovation Centre China ($100M investment)
• University of Washington St Louis – Investigation in to Alzheimer’s
Disease to find better ways of diagnosis and treatment
• Columbia University Medical Center – Identification of new targets and
novel therapies for type 2 diabetes and obesity
• Virginia Tech and Mayo Clinic – licensing agreement for the triple
reuptake inhibitor for treatment of depression
• University of Texas MD Anderson Cancer Center – Studying cancer
related pain
• Clinical studies and alliances with several US cancer institutes including
Mass General Hospital, Vanderbilt-Ingram Cancer Center, University of
Colorado and National Cancer Institue
Technology Collaborations
Proprietary and Confidential © AstraZeneca 2008
FOR INTERNAL USE ONLY
• Silence Therapeutics – novel system for using siRNA molecules to
target respiratory disease
• Cell Signaling Technology – PhosphoScan R – CST generated
antibodies to phosphorylated peptides used to IP proteins from cell
lysates. These are analysed by LC-MS to monitor changes in the levels
of phosphorlyation within the cell during treatment with potential kinase
inhibitors
• Astex Therapeutics – fragment based drug discovery – expertise in
NMR screening, crystalography and Isothermal calorimetry
Building a partnership with AstraZeneca
Proprietary and Confidential © AstraZeneca 2008
FOR INTERNAL USE ONLY
• Strategic Planning and Business Development (SPBD) Group
• Main role is to manage in-licensing activities
• Aligned with therapy areas
• Also involved with out licensing, spin offs, risk sharing deals
• Established a Master agreement system for main collaborators
• Manchester Cancer Research Centre
• Royal Marsden Hospital
• NKI-AVL – Netherlands Cancer Institute
• Strategic Alliances Group
• Science and Technology Alliances Group
• Collaborations relating to technology which is applicable across therapy
areas
• Advanced Science and Technology Lab – ASTL
Areas of interest
•
•
•
•
Proprietary and Confidential © AstraZeneca 2008
FOR INTERNAL USE ONLY
Chemistry
•
New synthetic methodologies
•
Novel lead generation technologies
•
Predictive QSAR methodologies
Predictive Biology
•
High Content Screening technologies
•
Novel physiological cell based efficacy screening technologies
•
Target validation methodologies
•
Improved methodologies to predict safety/toxicity
•
In silico simulation
•
In vivo predictive models
•
In vivo imaging
Predictive medicine
•
Rapid biomarker analysis techniques
•
Imaging to provide functional measurements of disease activity
Knowledge management/informatics
•
Structured searching and text mining
•
Patent informatics
Funding
•
Proprietary and Confidential © AstraZeneca 2008
FOR INTERNAL USE ONLY
Internal Innovation funding
• <$1M
• Should not include capital purchases
• Aim to identify new and novel technologies to improve our lead generation
screening capability
•
Partnerships with charitable organisations and governments
• BBSRG, MRC etc
•
Corporate funding
• Direct from research areas – very limited
•
Risk sharing deals
• AZ contribute with resources and knowledge
•
FTE
•
Lab space
•
Compound libraries
•
Chemistry
•
In vitro/ In vivo testing
• Share rewards between AZ and academic/biotech
What can AZ offer
Proprietary and Confidential © AstraZeneca 2008
FOR INTERNAL USE ONLY
•
Large and ever expanding compound collection
•
4 HTS centres across the globe supporting 6 therapy areas
• 2 in UK
• 1 in Sweden
• 1 in USA
•
Highly automated screening platforms for both primary and secondary
screening
• Systems from many suppliers
•
Beckman – motorman core systems
•
Agilent (V11) - Biocells
•
The Automation Partnership - Asset
•
RTS
•
HighRes Biosolutions – Microstar systems
•
ThermoFisher – CRS F3 automation systems
•
PAA – Elisa workstations and integrated acoustic dispensing systems
•
Extensive experience and proven track record in drug discovery
•
Technology teams (ASTL, CTT) – role is to evaluate new technologies
Contact information
Proprietary and Confidential © AstraZeneca 2008
FOR INTERNAL USE ONLY
• Chris Yochim – SPBD External Relations
[email protected]
•
Iain Comley – Science and Technology Alliances
[email protected]
• Kay Tait – Oncology and Infection SPBD [email protected]
• Jonathan Wingfield – Cancer Technology Team
[email protected]